Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden

Among the 26 micro-companies, the IPO guide's reviewers found an average of 2.9 flags. The IPO guide's jury has chosen to nominate Cessatech as the winner. The IPO guide did not find a flag at Cessatech's listing and the company had the best price development of the two micro companies with zero flags.

Affärsvärlden's IPO guide examines all Swedish stock exchange listings. In 2020, 47 companies were listed on the stock exchange. The IPO guide did not find a flag at Cessatech's listing and the company had the best price development of the two micro companies with zero flags. In the quality class, Danish Cessatech took home the award. Affärsvärlden did not raise any warning flags and recommended subscribing to the share listed on Spotlight in Denmark on 16 December. The share was oversubscribed 6 times over and after a good start, it is today about 75% higher.

https://www.affarsvarlden.se/artikel/

Comment from Jes Trygved, CEO of Cessatech: This is the second award this year, and we are truly proud and extremely happy for the recognition by Affärsvärlden, one of the leading business journals in the Nordics. Thanks to the team for the hard work related to the listing, and for staying on track with our development activities during an extremely difficult time with COVID19. As with children, the first years will often define their identity - I hope it will be the same for Cessatech. 
 

For more information, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech A/S: Cessatech’s business model offers unique, scalable economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile. The drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a focused development plan can be applied for documenting good effect in children. Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures.

Subscribe